Epigenetics in Cancer

Dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible, and thus make a promising therapeutic target.

Epigenetics in Cancer Products Targets

Products for Epigenetics in Cancer - Page 7

Cat.No. Product Name Information/Activity
BCC5608 TC-E 5002 1453071-47-0
BCC7791 Tranylcypromine hydrochloride Tranylcypromine is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively.
BCC5624 A 366 A-366 is a potent histone methyltransferase G9a inhibitor with an IC50 of 3.3 nM.
BCC5161 Cyproheptadine hydrochloride Cyproheptadine hydrochloride is a histamine receptor antagonist for 5-HT2 receptor with IC50 of 0.6 nM.
BCC2218 EPZ004777 EPZ004777 is a potent, selective DOT1L inhibitor with an IC50 of 0.4 nM.
BCC7432 Ryuvidine 265312-55-8
BCC2430 UNC 0224 UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 2.6 nM, an IC50 of 15 nM and a Kd of 23 nM. UNC0224 also potently inhibits b>GLP
BCC8014 UNC 0642 Potent and selective G9a and GLP inhibitor,UNC0642 is a potent and selective G9a/GLP inhibitor, inhibits G9a/GLP with an IC50 of less than 2.5 nM.
BCC2431 UNC 0646 UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC50 of 6 nM. UNC0646 is also a potent GLP inhibitor (IC50 <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 26 nM.
BCC4552 UNC1999 UNC1999 is a SAM-competitive, potent and selective inhibitor of EZH2/1 with IC50s of <10 nM and 45 nM, repectively.